Most Recent Articles by Mario Sznol, MD
VEGF and PD-1 pathway inhibitors show promising improvements compared with single-agent VEGF pathway inhibitors.
Mario Sznol, MD, of the Yale University School of Medicine in New Haven, Connecticut, discusses melanoma clinical trial results just published in the Journal of Clinical Oncology.
Study results presented at ASCO point to a major advance for immune therapy in advanced CEA-expressing CRC and possibly other CEA-expressing malignancies.
Immune therapies hold substantial promise to improve therapeutic options for patients with metastatic renal cancer.
Mario Sznol, MD, comments on the results of his phase 1 study reporting on data from patients with metastatic melanoma treated with nivolumab.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- Moving Targets: Off-Label Prescribing of Targeted Therapies
- New Algorithm Improves Outcome Prediction for Diffuse Large B-Cell Lymphoma
- 2-Year TKI Consolidation Allowed for TKI Cessation in Select Patients With CML
- Trial Identifies Marker for Response to Immunotherapy in Esophageal Cancer
- Immunotherapy Combo in Head and Neck Cancer Shows Activity in Phase 2 Trial
- Study Finds Real-World Data on Cardiac Toxicity of Trabectedin May Be Limited
- POT1 Revealed as a Sarcoma Predisposition Gene
- IMRT Linked to Fewer Instances of Local Recurrence in Sarcoma: A Long-Term Follow-Up
- Study Adds More Evidence to Support Active Surveillance as the Standard of Care for Certain Desmoid Tumors
- Palliative Care and Survivorship